OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
Jingen Zhu, Swati Jain, Jian Sha, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 25

Showing 25 citing articles:

Understanding Bacteriophage Tail Fiber Interaction with Host Surface Receptor: The Key “Blueprint” for Reprogramming Phage Host Range
Jarin Taslem Mourosi, Ayobami Awe, Wenzheng Guo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12146-12146
Open Access | Times Cited: 84

Bacteriophage T4 Head: Structure, Assembly, and Genome Packaging
Venigalla B. Rao, Andrei Fokine, Qianglin Fang, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 527-527
Open Access | Times Cited: 26

Design of bacteriophage T4-based artificial viral vectors for human genome remodeling
Jingen Zhu, Himanshu Batra, Neeti Ananthaswamy, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23

A Comprehensive Review on Phage Therapy and Phage-Based Drug Development
Longzhu Cui, Shinya Watanabe, Kazuhiko Miyanaga, et al.
Antibiotics (2024) Vol. 13, Iss. 9, pp. 870-870
Open Access | Times Cited: 11

Aspects of Phage-Based Vaccines for Protein and Epitope Immunization
Marco Palma
Vaccines (2023) Vol. 11, Iss. 2, pp. 436-436
Open Access | Times Cited: 18

Mucosal vaccines for viral diseases: Status and prospects
Bingjie Ma, Mengxiao Tao, Zhili Li, et al.
Virology (2024) Vol. 593, pp. 110026-110026
Closed Access | Times Cited: 6

The frontier of health: Exploring therapeutic potentials of the microbiome
Mohammad Abavisani, Sobhan Karbas Foroushan, Prashant Kesharwani, et al.
PharmaNutrition (2025), pp. 100435-100435
Closed Access

CRISPR-Cas: a game-changer in vaccine development and the fight against viral infections
Fayu Yang, Saba R. Aliyari, Zixiang Zhu, et al.
Trends in Microbiology (2025)
Closed Access

A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines
Ming Hong, Tin Lan, Qiuxia Li, et al.
Gut Microbes (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 12

Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?
Christian Devaux, Pierre Pontarotti, Anthony Levasseur, et al.
Frontiers in Public Health (2024) Vol. 11
Open Access | Times Cited: 4

Bacteriophage T4 as a nanovehicle for delivery of genes and therapeutics into human cells
Venigalla B. Rao, Jingen Zhu
Current Opinion in Virology (2022) Vol. 55, pp. 101255-101255
Open Access | Times Cited: 14

Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses
Marianna Teixeira de Pinho Favaro, Patricia Álamo, Nerea Roher, et al.
ACS Materials Letters (2024) Vol. 6, Iss. 3, pp. 954-962
Open Access | Times Cited: 2

A comprehensive review of oral microenvironment changes and orofacial adverse reactions after COVID‐19 vaccination: The good, the bad, and the ugly
Shaghayegh Najary, Mohammadreza Vatankhah, Gita Khadivi, et al.
Health Science Reports (2024) Vol. 7, Iss. 3
Open Access | Times Cited: 2

Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis
Han Zhong, Yang Zhou, Shuya Mei, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 13

T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines
Mengling Li, Cen Chen, Xialin Wang, et al.
Antiviral Research (2023) Vol. 217, pp. 105688-105688
Closed Access | Times Cited: 6

Evaluation of Anti-SARS-CoV-2 IgA Response in Tears of Vaccinated COVID-19 Subjects
Irene Soffritti, Maria D’Accolti, Carla Enrica Gallenga, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 399-399
Open Access | Times Cited: 5

Phage based vaccine: A novel strategy in prevention and treatment
Sharareh Mohammad Hasani, Elham Ghafouri, Seyed Amin Kouhpayeh, et al.
Heliyon (2023) Vol. 9, Iss. 9, pp. e19925-e19925
Open Access | Times Cited: 5

Bacteriophage as a Potential Biotherapeutics to Combat Present-Day Crisis of Multi-Drug Resistant Pathogens
Ananya Pattnaik, Sanghamitra Pati, Sangram Keshari Samal
Heliyon (2024), pp. e37489-e37489
Open Access | Times Cited: 1

Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?
Harald Brüssow
Microbial Biotechnology (2022) Vol. 16, Iss. 1, pp. 3-14
Open Access | Times Cited: 8

Reaching the Final Endgame for Constant Waves of COVID-19
Norman A. Ratcliffe, Helena Carla Castro, Marcelo Salabert Gonzalez, et al.
Viruses (2022) Vol. 14, Iss. 12, pp. 2637-2637
Open Access | Times Cited: 5

Current Advances in Viral Nanoparticles for Biomedicine
Xianxun Sun, Tao Tian, Yindong Lian, et al.
ACS Nano (2024)
Closed Access

Potentiating Virus-like Particles for Mucosal Vaccination Using Material Science Approaches
Milad Radiom
Colloids and Interfaces (2024) Vol. 8, Iss. 6, pp. 68-68
Open Access

A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?
Zahra Salehi, Mohammad Javad Rasaee
Vaccines (2023) Vol. 11, Iss. 4, pp. 833-833
Open Access | Times Cited: 1

Bacteriophage-based Vaccine: A New Dawn for Vaccine Design and Development
Fazal Mehmood Khan
Proceedings of the Pakistan Academy of Sciences B Life and Environmental Sciences (2023) Vol. 60, Iss. S, pp. 107-114
Open Access

Page 1

Scroll to top